Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 47-51

  Richardson, D L ^a   Backes, F J ^a   Hurt, J D ^a   Seamon, L G ^a   Copeland, L J ^a   Fowler, J M ^a   Cohn, D E ^a   O'Malley, D M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab; Bowel perforation; Epithelial ovarian cancer; Fistula; Risk factors

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; DISEASE ASSOCIATION; DYING; ENTEROCUTANEOUS FISTULA; FEMALE; HUMAN; INTESTINE FISTULA; INTESTINE PERFORATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; RECTOVAGINAL NODULARITY; RECTUM DISEASE; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK FACTOR; UNIVARIATE ANALYSIS; VAGINA DISEASE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INTESTINAL PERFORATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953290179     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.011     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer Statistics, 2008. CA. Cancer. J. Clin. 58 (2008) 71-96
2. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
3. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25 (2007) 5180-5186
4. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102 (2006) 140-144
5. Wright J.D., Secord A.A., Numnum T.M., Rocconi R.P., Powell M.A., Berchuck A., et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int. J. Gynecol. Cancer Jul. 21 (2007) 1-7
6. Nimeiri H.S., Oza A.M., Morgan R.J., Friberg G., Kasza K., Faoro L., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia. Gynecol. Oncol. 110 (2008) 49-55
7. Chura J.C., Van Iseghem K., Downs L.S., Carson L.F., and Judson P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol. Oncol. 107 (2007) 326-330
8. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J. Clin. Oncol. 26 (2008) 76-82
9. Richardson D.L., Backes F.J., Seamon L.G., Zanagnolo V., O'Malley D.M., Cohn D.E., et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 111 (2008) 461-466
10. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer 107 (2006) 83-89
11. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107 (2007) 118-123
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
13. Guppy A.E., and Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer?. Oncologist 7 (2002) 437-443
14. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J. Clin. Oncol. 25 (2007) 1539-1544
15. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
16. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23 (2005) 3697-3705
17. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23 (2005) 8033-8040
18. Ko A.H., Dito E., Schillinger B., et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. Invest. New Drugs 26 (2008) 463-471
19. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann. Oncol. 19 (2008) 577-582
20. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 17 (2007) 771-776
21. U.S. National Institutes of Health. Clinical trials information. Available from URL http://clinicaltrials.gov/ct2/show/NCT00483782?term = ovarian+cancer+AND+bevacizumab and rank = 11 [accessed June 5, 2009].